UBT251

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

ObesityInteractionOverweightHepatitisPhase II Clinical StudySleep

190 competitors in Obesity

#DrugCompanyPhaseTrials

1

Retatrutide

Eli Lilly

Phase 3

62

Enavogliflozin

Daewoong Pharmaceutical Co. LTD.

Phase 3

13

UBT251

Novo Nordisk

Phase 3

24

Gemtesa

Sumitomo Pharma America, Inc.

Phase 3

15

Berobenatide

Pfizer

Phase 3

36

Eloralintide

Eli Lilly

Phase 3

107

Ribupatide

KKailera

Phase 3

38

Efsubaglutide Alfa

SShanghai Yinnuo Pharmaceutical Technology Co., Ltd.

Phase 3

19

Survodutide

Boehringer Ingelheim

Phase 3

210

Avapro

Sanofi

Preclinical

1Show 35 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Obesity2 trials

A Single-Centre, Open-Label Study of the Effect of UBT251 on Pharmacokinetics of an Oral Combination Contraceptive (Ethinylestradiol and Levonorgestrel) and Gastric Emptying in Women of Non-Childbearing Potential With Overweight or Obesity

Recruiting·Novo Nordisk·Phase 1·NCT07710729·40 enrolled

An Open-label, Single-sequence, Crossover Study Investigating the Influence of UBT251 on Pharmacokinetics of Index Substrates for Cytochrome P450 Enzymes in Participants With Overweight or Obesity

Recruiting·Novo Nordisk·Phase 1·NCT07710768·44 enrolled

Phase II Clinical Study1 trial

UBT251 Injection Phase II Clinical Study (CKD)

Recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 2·NCT07134335·180 enrolled

Hepatitis1 trial

A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 2·NCT07145151·156 enrolled

Overweight1 trial

A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity

Recruiting·Novo Nordisk·Phase 2·NCT07395687·333 enrolled

Type 2 Diabetes1 trial

A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Phase III Trial to Evaluate the Efficacy and Safety of UBT251 Injection in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Diet and Exercise Alone（UNIGUIDE-1）

Recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 3·NCT07659574·360 enrolled

4 more indications

Diabetes Mellitus, Type 21 trial

Efficacy and Safety of Once-weekly Subcutaneous UBT251 in Participants With Type 2 Diabetes - a Dose-finding Study

Recruiting·Novo Nordisk·Phase 2·NCT07668388·300 enrolled

Obstructive Sleep Apnea1 trial

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese Participants With Moderate-to-Severe Obstructive Sleep Apnea (OSA) on Positive Airway Pressure (PAP) Therapy（UNISHAPE-OSA-2）

Not yet recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 3·NCT07806851·150 enrolled

Sleep1 trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of UBT251 Injection in Obese Participants With Moderate-to-severe Obstructive Sleep Apnea (OSA) Not on Positive Airway Pressure (PAP) Therapy（UNISHAPE-OSA-1）

Not yet recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 3·NCT07767942·150 enrolled

Unspecified1 trial

A Phase 1, Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of UBT251 on the Pharmacokinetics of Single Oral Doses of Metformin, Warfarin, Atorvastatin, and Digoxin in Overweight or Obese Participants.

Recruiting·TThe United Bio-Technology (Hengqin) Co., Ltd.·Phase 1·NCT07785934·48 enrolled

Details

Drug Info

Related News